共 50 条
- [1] Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Brahmer, J. R.Topalian, S. L.Powderly, J.Wollner, I.Picus, J.Drake, C. G.Stankevich, E.Korman, A.Pardoll, D.Lowy, I.
- [2] Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Hodi, F. StephenSznol, MarioMcDermott, David F.Carvajal, Richard D.Lawrence, Donald P.Topalian, Suzanne LouiseWigginton, JonMcDonald, DanKollia, GeorgiaGupta, Ashok KumarSosman, Jeffrey Alan
- [3] Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Brahmer, J. R.Topalian, S.Wollner, I.Powderly, J. D.Picus, J.Drake, C.Covino, J.Korman, A.Pardoll, D.Lowy, I.
- [4] Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for responseJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Topalian, Suzanne LouiseBrahmer, Julie R.Hodi, F. StephenMcDermott, David F.Smith, David C.Gettinger, Scott N.Taube, Janis M.Drake, Charles G.Pardoll, Drew M.Antonia, ScottSpigel, David R.Atkins, Michael B.Lawrence, Donald P.McDonald, DanJure-Kunkel, MariaKorman, AlanKollia, GeorgiaGupta, Ashok KumarWigginton, JonSznol, Mario
- [5] Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients (Pts) with Advanced Non-Small-Cell Lung Cancer (NSCLC)JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204Brahmer, J. R.Horn, L.Antonia, S. J.Spigel, D.Gandhi, L.Sequist, L.Wigginton, J. M.Kollia, G.Gupta, A.Gettinger, S.
- [6] Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC)JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)McDermott, David F.Drake, Charles G.Sznol, MarioChoueiri, Toni K.Powderly, JohnSmith, David C.Wigginton, JonMcDonald, DanKollia, GeorgiaGupta, Ashok KumarAtkins, Michael B.
- [7] Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Sznol, M.Powderly, J. D.Smith, D. C.Brahmer, J. R.Drake, C. G.McDermott, D. F.Lawrence, D. P.Wolchok, J. D.Topalian, S. L.Lowy, I.
- [8] Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Brahmer, Julie R.Horn, LeoraAntonia, ScottSpigel, David R.Gandhi, LeenaSequist, Lecia V.Wigginton, JonMcDonald, DanKollia, GeorgiaGupta, Ashok KumarGettinger, Scott N.
- [9] Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2021, 27 (13) : 3620 - 3629Curigliano, GiuseppeGelderblom, HansMach, NicolasDoi, ToshihikoTai, DavidForde, Patrick M.Sarantopoulos, JohnBedard, Philippe L.Lin, Chia-ChiHodi, F. StephenWilgenhof, SofieSantoro, ArmandoSabatos-Peyton, Catherine A.Longmire, Tyler A.Xyrafas, AlexandrosSun, HaiyingGutzwiller, SabineManenti, LuigiNaing, Aung
- [10] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumorsANNALS OF ONCOLOGY, 2018, 29Deva, S.Lee, J-S.Lin, C-C.Yen, C-J.Millward, M.Chao, Y.Keam, B.Jameson, M.Hou, M-M.Kang, Y-K.Markman, B.Lu, C-H.Rau, K-M.Lee, K-H.Horvath, L.Friedlander, M.Hill, A.Wu, J.Hou, J.Desai, J.